Back to search
FDAFDA · Food and drugs·Recall number D-0411-2025

Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsules per bottle, Rx Only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. NDC#: 70518-3772-02

Published May 14, 2025 · Recall initiated: April 22, 2025

Summary

FDA records drug Class II recall D-0411-2025, published May 14, 2025 and initiated April 22, 2025. Recalling firm: RemedyRePack Inc.; Status: Ongoing; Reported quantity: 23 bottles/30 count- 690 capsules; Lot: Lot#: B3698036-033125, B3688703-032625, Exp.: 07/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRePack Inc.
Distributor
Within U.S - PA, VA, FL.
Lot
Lot#: B3698036-033125, B3688703-032625, Exp.: 07/31/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsules per bottle, Rx Only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. NDC#: 70518-3772-02 recalled?

Yes. FDA published recall D-0411-2025 on May 14, 2025. Reported hazard: CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail